Literature DB >> 8247533

Ionizing radiation and UV induction of p53 protein by different pathways in ataxia-telangiectasia cells.

K K Khanna1, M F Lavin.   

Abstract

Cell cycle anomalies have been described in ataxia-telangiectasia cells after exposure to ionizing radiation. A recent report demonstrates that cells from these patients lack the ionizing radiation-induced increase in p53 protein seen in controls. We report here that an ionizing radiation-induced p53 response is reduced and/or delayed in cells from four ataxia-telangiectasia complementation groups. On the other hand, p53 induction is normal in all A-T complementation groups after exposure to UV-B light, an agent to which these cells are not hypersensitive. Specific inhibitors of protein kinase C and serine/threonine phosphatases prevented the radiation induction of p53 protein. Agents that produced double-strand breaks in DNA and/or inhibition of transcription caused an induction of p53 in the absence of radiation in control cells but not in ataxia-telangiectasia, but inhibitors of cell cycle progression such as mimosine and aphidicolin led to an increase in p53 in both cell types in the absence of radiation. These results suggest that there is more than one signal transduction pathway responsible for activation of p53, one of which is less efficient in ataxia-telangiectasia cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8247533

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  54 in total

1.  Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage.

Authors:  N H Chehab; A Malikzay; E S Stavridi; T D Halazonetis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

Review 2.  DNA replication blockade impairs p53-transactivation.

Authors:  R Takimoto; W S El-Deiry
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

3.  Purification and DNA binding properties of the ataxia-telangiectasia gene product ATM.

Authors:  G C Smith; R B Cary; N D Lakin; B C Hann; S H Teo; D J Chen; S P Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

4.  Spontaneous and oxidative stress-induced programmed cell death in lymphocytes from patients with ataxia telangiectasia (AT).

Authors:  R Schubert; J Reichenbach; N Royer; M Pichler; S Zielen
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

5.  Requirement of ATM in phosphorylation of the human p53 protein at serine 15 following DNA double-strand breaks.

Authors:  K Nakagawa; Y Taya; K Tamai; M Yamaizumi
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

Review 6.  Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress.

Authors:  M Ljungman
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

7.  Isolation of full-length ATM cDNA and correction of the ataxia-telangiectasia cellular phenotype.

Authors:  N Zhang; P Chen; K K Khanna; S Scott; M Gatei; S Kozlov; D Watters; K Spring; T Yen; M F Lavin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

8.  Nijmegen breakage syndrome cells fail to induce the p53-mediated DNA damage response following exposure to ionizing radiation.

Authors:  W Jongmans; M Vuillaume; K Chrzanowska; D Smeets; K Sperling; J Hall
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

9.  Involvement of novel autophosphorylation sites in ATM activation.

Authors:  Sergei V Kozlov; Mark E Graham; Cheng Peng; Philip Chen; Phillip J Robinson; Martin F Lavin
Journal:  EMBO J       Date:  2006-07-13       Impact factor: 11.598

10.  The product of the ataxia-telangiectasia group D complementing gene, ATDC, interacts with a protein kinase C substrate and inhibitor.

Authors:  P M Brzoska; H Chen; Y Zhu; N A Levin; M H Disatnik; D Mochly-Rosen; J P Murnane; M F Christman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.